p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer

Clinical Cancer Research

Volumn 8, Issue 5, 2002, Pages 973-985

  Leonard, Debra G B ^a   Travis, Lois B ^d   Addya, Kathakali ^a   Dores, Graca M ^d   Holowaty, Eric J ^e   Bergfeldt, Kjell ^f   Malkin, David ^g   Kohler, Betsy A ^h   Lynch, Charles F ⁱ   Wiklund, Tom ^j   Stovall, Marilyn ^k   Hall, Per ^f   Pukkala, Eero ^l   Slater, Diana J ^b   Felix, Carolyn A ^b,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e CANCER CARE ONTARIO   (Canada)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g HOSPITAL FOR SICK CHILDREN   (Canada)

^h NEW JERSEY DEPARTMENT OF HEALTH AND SENIOR SERVICES   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^k UNIVERSITY OF TEXAS   (United States)

^l FINNISH CANCER REGISTRY   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GYRASE INHIBITOR; IFOSFAMIDE; MELPHALAN; METHOTREXATE; MITOMYCIN; PLATINUM DERIVATIVE; PROTEIN P53; VINBLASTINE;

AMINO ACID SUBSTITUTION; ARTICLE; COHORT ANALYSIS; CROSS LINKING; DNA DAMAGE; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; KARYOTYPE; LEUKEMIA; MYELODYSPLASTIC SYNDROME; OVARY CANCER; PHASE TRANSITION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CISPLATIN; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LEUKEMIA; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0036091220     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Chemotherapy-related second cancers
2. Multiple myeloma and acute myelomonocytic leukemia: Report of four cases possibly related to melphalan
3. The secondary leukemias: Challenges and research directions
4. Second cancers following radiotherapy
5. Secondary leukemias induced by topoisomerase targeted drugs
6. The p53 gene in pediatric therapy-related leukemia and myelodysplasia
7. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations
8. Association of germline p53 replication error with myelodysplastic syndrome following osteosarcoma treatment
9. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype and a poor prognosis
10. Clinical pharmacology of cancer chemotherapy
11. Alkylating agents
12. Is cisplatin a human carcinogen?
13. Platinum analogues
14. Secondary acute non-lymphoblastic leukemia in two children following treatment with a cis-diamminechloroplatinum-II-based regimen for osteosarcoma
15. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangement of chromosome 11q
16. Secondary leukemia associated with a conventional dose of etoposide: Review of serial germ cell tumor protocols
17. Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumours
18. Secondary myelodysplastic syndrome complicating therapy for osteogenic sarcoma
19. Ovarian cancer: Screening, treatment, and follow-up: NIH Consensus Development Panel on Ovarian Cancer
20. Risk of leukemia after platinum-based chemotherapy for ovarian cancer
21. Treatment-related leukemia following testicular cancer
22. Mutations of the p53 gene do not occur in testis cancer
23. Potential role for wild-type p53 in leukemias with MLL gene translocations
24. Hereditary and acquired p53 mutations in childhood acute lymphoblastic leukemia
25. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma
26. High dose cisplatin and high dose carboplatin in refractory ovarian cancer
27. Polymorphism at codon 213 within the p53 gene
28. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease
29. p53 mutations in cyclophosphamide-associated bladder cancer
30. Mutations in the p 53 gene in myelodysplastic syndromes
31. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia
32. In vitro mutational specificity of cisplatin in the human hypoxanthine guanine phosphoribosyltransferase gene
33. Sequence specificity of mutation induced by the anti-tumor drug cisplatin in the CHO aprt gene
34. p53 and the Li-Fraumeni syndrome
35. Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families
36. Association of germline p53 mutation with MLL segmental jumping translocation in treatment-related leukemia
37. p53 mutations associated with breast, colorectal, liver, lung, and ovarian cancers
38. Comprehensive genotypic analysis of leukemia: Clinical and therapeutic implications
39. Molecular biology of chemotherapy-related leukemias. 2001 Educational Book
40. Leukemias related to treatment with DNA topoisomerase II inhibitors
41. Activating RAS mutations in therapy-related myeloid disorders associated with deletions of chromosomes 5 and 7
42. RAS mutations in pediatric leukemias with MLL gene rearrangements
43. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders
44. Sequential development of Wilms tumor, T-cell acute lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with Type 1 neurofibromatosis: A clinical and cytogenetic case report
45. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1
46. Frequent jumping translocations of chromosomal segments involving the ABL oncogene alone or in combination with CD3-MLL genes in secondary leukemias
47. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53
48. Duplication or amplification of chromosome band 1q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents
49. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model
50. Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyo-type and are unrelated to type of previous therapy
51. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype
52. Association of CYP3A4 genotype with treatment-related leukemia
53. 609C→T polymorphism in the NAD(P)H: Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
54. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia
55. Detection of single nucleotide polymorphisms with the WAVE DNA fragment analysis system
56. p53 gene mutations in pediatric brain tumors
57. Polymorphism at codon 36 of the p53 gene
58. A novel germline p53 splicing mutation in a pediatric patient with a second malignant neoplasm
59. Absence of hereditary p53 mutations in ten familial leukemia pedigrees
60. Complex replication error causes p53 mutation in a Li-Fraumeni family
61. Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations
62. Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double stranded PCR products and DNA fragments: Evidence for solvent-induced bends in DNA heteroduplexes
63. Denaturing HPLC-identified novel FBN1 mutations, polymorphisms, and sequence variants in Marfan syndrome and related connective tissue disorders
64. Blind analysis of denaturing high-performance liquid chromatography as a tool for mutation detection
65. De novo deletions of p53 gene and wild-type p53 correlate with acquired cisplatin-resistance in human osteosarcoma OST cell line
66. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio
67. 2 to M transition: Implications for gene therapy
68. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity